Roche announced that the CHMP has recommended the approval of Susvimo (ranibizumab injection) 100 mg/mL for the treatment of neovascular age-related macular degeneration (nAMD). Susvimo is intended for… read more.
Organon will present results from a post hoc analysis of pooled data from the Phase 3 pivotal trials, ADORING 1 and ADORING 2, evaluating the efficacy and safety… read more.
In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers predict that the anticipated price reductions of up to 70% will dramatically… read more.
Chiesi announces MHRA approval in the UK of Clenil Modulite (beclometasone; 100 mcg and 200 mcg) formulated with a next-generation, non-PFAS, low GWP propellant. These are the first… read more.
Celcuity Inc. announced that the FDA approved Revtorpyk (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally… read more.
The American Gastroenterological Association (AGA) today announced the launch of Nigel, an artificial intelligence (AI)-powered virtual assistant developed exclusively for gastroenterology and hepatology. Built using AGA’s trusted clinical guidance and developed in collaboration… read more.
Nearly one in four U.S. workers (24%) say they are currently in a job they want to quit but stay with their employer for the health insurance, according… read more.
Johnson & Johnson announced that the FDA approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform (DE STSF), an integrated catheter ablation solution that enables electrophysiologists to deliver both… read more.
An international research team led by the Medical University of Vienna has investigated a new peptide derived from cone snail venom which significantly reduced inflammation-induced pain in an… read more.
A UVA Health emergency medicine doctor and colleague at Clemson University have developed a framework to help hospitals integrate artificial intelligence to not just increase efficiency and cut… read more.
Shionogi & Co announced the FDA has accepted a Supplemental New Drug Application (sNDA) for Fetroja (cefiderocol) for the treatment of pediatric patients (at least 26 weeks of… read more.
When schools closed in the spring of 2020 at the onset of the COVID-19 pandemic, the number of children and adolescents receiving mental health treatment in the United… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
